Higher-riskArticle link

How Cholinesterase Inhibitors and Memantine Work (and Realistic Expectations)

If your loved one has been prescribed donepezil, rivastigmine, galantamine, or memantine for Alzheimer's, you're likely hoping for a clear improvement. These medications work by boosting key brain chemicals, but they are not cures—they are tools to help maintain function for a longer period. The effects are often subtle, and individual responses vary widely. This guide explains exactly how each drug works, what you can realistically expect, and how to partner with your clinician to find the best approach for your family.

Key points

  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) boost acetylcholine to help with memory and thinking; memantine protects neurons from overstimulation by glutamate.
  • Expect modest, not dramatic, benefits—the goal is to slow decline, not reverse it. Many people see no obvious change, but the drug may still be helping.
  • Side effects like nausea, dizziness, and low heart rate are common in the first few weeks. Report them to the clinician; do not stop the drug abruptly.
  • The rivastigmine patch can reduce gastrointestinal side effects and is a good option for those who have trouble swallowing pills.
  • Annual medication reviews are essential to identify and remove anticholinergic drugs that can make dementia worse.
  • Individual responses vary; work closely with the clinician to find the right drug, dose, and combination for your loved one.

The Brain Chemistry Behind the Medications

In Alzheimer's disease, two key chemical messengers (neurotransmitters) become unbalanced. Acetylcholine, which is crucial for memory and thinking, is in short supply because the enzyme that normally breaks it down (acetylcholinesterase) becomes overactive. At the same time, another chemical called glutamate can become too abundant, overstimulating brain cells and potentially causing them to become stressed or damaged. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) work by blocking that overactive enzyme, allowing more acetylcholine to stay in the brain and improving communication between nerve cells. Memantine, on the other hand, acts as a gentle brake on the glutamate system, protecting neurons from being overexcited.

What to Expect: Modest, Not Miraculous

In clinical studies, these medications produce small but measurable improvements in cognition for some people. Many families report that the benefit is subtle—perhaps the person stays at a certain functional level for a few extra months, or they seem a bit more alert and engaged. It is rare to see a dramatic reversal of symptoms. As one expert put it, these drugs are like 'propping things up for a longer period' rather than turning back the clock. Some people do not notice any change at all, and that is normal. The goal is to slow the rate of decline, not to stop it entirely. It is also important to know that these drugs can help with behavioral symptoms in some cases, though evidence is mixed. For example, rivastigmine has shown some benefit for hallucinations in Lewy body dementia, but overall, the impact on behavior is not guaranteed.

Differences Between the Drugs

While all three cholinesterase inhibitors share the same main action, they have subtle differences. Donepezil is a selective inhibitor that primarily targets the brain, and it has a long half-life, allowing for once-daily dosing, which can help with compliance. Rivastigmine inhibits two related enzymes (acetylcholinesterase and butyrylcholinesterase), which may provide a wider effect but also can lead to more gastrointestinal side effects. Galantamine has a dual action: it inhibits the enzyme and also sensitizes nicotinic receptors, potentially enhancing the brain's response to the acetylcholine that is available. However, the clinical significance of these differences is still uncertain. Memantine is often added later, typically in moderate to severe stages, and it works through a completely different mechanism. Some studies suggest that combining a cholinesterase inhibitor with memantine may offer additional benefit for some patients.

General caregiving information, not medical advice. Check medications and major care changes with your clinician.

Step-by-step

  1. Ask the prescribing clinician what specific changes to watch for in the first 3 months, common side effects, and how to handle them—then write down the answers.

  2. Follow dosing instructions: donepezil once daily at bedtime to reduce nausea; rivastigmine and galantamine oral forms twice daily; memantine started low and gradually increased. Use a pill organizer or phone alarm.

  3. If nausea or swallowing pills is problematic, ask about the rivastigmine transdermal patch—fewer GI side effects. Apply to a clean, dry, hairless area and rotate sites daily.

  4. Watch for nausea, vomiting, diarrhea, dizziness, headache, or drowsiness in the first weeks. Check pulse regularly; if below 60 bpm or if faint, dizzy, or short of breath, contact the clinician immediately. Do not stop abruptly without guidance.

  5. Keep a weekly log with one or two specific observations (e.g., 'remembered to shower without prompting') and side effects; bring it to follow-up appointments.

  6. If the clinician recommends stopping, ask about a gradual taper to avoid temporary worsening of cognition or behavior.

What not to do

  • Don't expect dramatic improvement; benefit is often subtle—maybe a few extra months of stability or more alertness—rather than sudden recovery.

  • Don't stop the medication abruptly; sudden withdrawal can cause rapid worsening of cognition and behavior.

  • Don't assume no obvious change means it's not working; the drug may be slowing decline rather than reversing it.

  • Don't ignore side effects like nausea or dizziness—they can lead to falls or dehydration. Report them promptly so the clinician can adjust the dose or route.

  • Don't combine with strong anticholinergic drugs (e.g., diphenhydramine, oxybutynin) without the clinician's knowledge; they block the acetylcholine the dementia drug aims to boost.

Practical tools

  • Weekly Symptom and Medication Log

    A notebook or phone note recording date, dose, side effects, and one specific behavioral observation per week (e.g., 'remembered my name'). Bring to appointments to help the clinician assess benefit.

  • Pill Organizer with Time-of-Day Slots

    Weekly organizer with morning, afternoon, and evening compartments to prevent missed or double doses. For the rivastigmine patch, note the day and application site to ensure daily rotation.

  • Clinician Conversation Script

    A short note by the phone: 'We started [medication] on [date] at [dose]. Since then, we've noticed [change]. Main side effect is [describe]. Should we continue, adjust, or switch?' Keeps calls focused and efficient.

  • Annual Medication Review Checklist

    Once a year, gather all prescriptions, OTC drugs, and supplements; ask the clinician: 'Are any anticholinergic? Could any worsen the dementia?' Especially important for those on multiple medications.

Discuss with your clinician

Ask your clinician: 'Is my loved one a candidate for a combination of a cholinesterase inhibitor and memantine? If so, when should we add the second drug?'

Discuss: 'What is the plan if my loved one develops significant side effects like a very slow heart rate or severe nausea? Should we stop the drug or switch to another one?'

Ask: 'Are there any other medications my loved one is taking that could interfere with these dementia drugs? Could we review all prescriptions and supplements for anticholinergic effects?'

If the person has Lewy body dementia, ask: 'Should we avoid antipsychotics? If behavioral symptoms become severe, what are the safest options?'

Discuss: 'How will we know if the medication is not working? At what point would you recommend stopping it, and how should we taper?'

Related guides

Sources